Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Swiss Med Wkly

Title: Swiss medical weekly

Publisher: EMH Swiss Medical Publishers, Ltd.

ISSN (Electronic): 1424-3997

ISSN (Print): 0036-7672

Publication date (Electronic): 2018

Volume: 148

Affiliations

[1 ] Division of Gastroenterology and Hepatology, University Hospital Zürich, Switzerland and Swiss HPB Centre.

[2 ] Division of Gastroenterology and Hepatology, Hospital St Gallen, Switzerland.

[3 ] Epatocentro Ticino, Lugano, Switzerland.

[4 ] Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Switzerland / Institute of Medical Virology, University of Zurich, Switzerland.

[5 ] Department of Biostatistics and Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland.

[6 ] Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Switzerland.

Article

Publisher Item ID: smw-14560

DOI: 10.4414/smw.2018.14560

PubMed ID: 29376557

SO-VID: 68448633-af82-4437-b05f-2bb863013664

History

Data availability:

Comments

Comment on this article

scite_

Cited by 9

See all cited by